Longeveron (LGVN) to Release Earnings on Tuesday

Longeveron (NASDAQ:LGVN) will likely be posting its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect Longeveron to post earnings of ($0.26) per share and revenue of $0.2850 million for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:30 PM ET.

Longeveron (NASDAQ:LGVN) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.02. Longeveron had a negative return on equity of 95.91% and a negative net margin of 894.40%.The firm had revenue of $0.32 million during the quarter, compared to analyst estimates of $0.41 million. On average, analysts expect Longeveron to post $-4 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Longeveron Stock Down 0.4%

Shares of Longeveron stock opened at $0.83 on Monday. Longeveron has a twelve month low of $0.63 and a twelve month high of $2.31. The business has a 50-day moving average price of $0.81 and a 200 day moving average price of $1.16. The firm has a market cap of $17.56 million, a PE ratio of -0.83 and a beta of 0.16.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Longeveron in a research note on Wednesday, October 8th. Roth Capital cut their price objective on Longeveron from $10.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, August 15th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.67.

Institutional Investors Weigh In On Longeveron

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd purchased a new stake in Longeveron Inc. (NASDAQ:LGVN) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned approximately 0.32% of Longeveron at the end of the most recent reporting period. 10.01% of the stock is currently owned by hedge funds and other institutional investors.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.